{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-028771","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.710325+00:00","generated_at":"2026-06-24T02:08:34.154316+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AbCellera Q2 2022 revenue rises to $46M, net loss widens to $7M; 4 new program starts","bullets":["Total revenue $45.9M, up 66% from $27.6M in Q2 2021; royalties from bebtelovimab contributed $33.2M.","Net loss $6.8M ($0.02/share) vs loss $2.3M ($0.01/share) in prior year, driven by higher R&D and G&A investments.","Added 4 program starts in Q2, cumulative 88 (+47% YoY); total programs under contract 164 (+19% YoY).","Six molecules cumulatively advanced to clinic, up from 4 at Q2 2021.","Cash & marketable securities $1.022B; R&D expenses $26.7M (+78% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-028771","json":"https://secwatch.observer/filing/0001564590-22-028771.json","markdown":"https://secwatch.observer/filing/0001564590-22-028771.md","text":"https://secwatch.observer/filing/0001564590-22-028771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022028771/0001564590-22-028771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022028771/abcl-8k_20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:08:34.154316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}